Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Functional characterization and optimization of a bacterial cyclic nucleotide-gated channel.

Morgan JLW, Evans EGB, Zagotta WN.

J Biol Chem. 2019 May 3;294(18):7503-7515. doi: 10.1074/jbc.RA119.007699. Epub 2019 Mar 18.

PMID:
30885945
2.

Copper- and Zinc-Promoted Interdomain Structure in the Prion Protein: A Mechanism for Autoinhibition of the Neurotoxic N-Terminus.

Evans EGB, Millhauser GL.

Prog Mol Biol Transl Sci. 2017;150:35-56. doi: 10.1016/bs.pmbts.2017.06.005. Epub 2017 Jul 31. Review.

PMID:
28838668
3.

Interaction between Prion Protein's Copper-Bound Octarepeat Domain and a Charged C-Terminal Pocket Suggests a Mechanism for N-Terminal Regulation.

Evans EG, Pushie MJ, Markham KA, Lee HW, Millhauser GL.

Structure. 2016 Jul 6;24(7):1057-67. doi: 10.1016/j.str.2016.04.017. Epub 2016 Jun 2.

4.

Genetic Incorporation of the Unnatural Amino Acid p-Acetyl Phenylalanine into Proteins for Site-Directed Spin Labeling.

Evans EG, Millhauser GL.

Methods Enzymol. 2015;563:503-27. doi: 10.1016/bs.mie.2015.06.008. Epub 2015 Jul 2.

5.

n-Dopants Based on Dimers of Benzimidazoline Radicals: Structures and Mechanism of Redox Reactions.

Zhang S, Naab BD, Jucov EV, Parkin S, Evans EG, Millhauser GL, Timofeeva TV, Risko C, Brédas JL, Bao Z, Barlow S, Marder SR.

Chemistry. 2015 Jul 20;21(30):10878-85. doi: 10.1002/chem.201500611. Epub 2015 Jun 18.

6.

Adapter reagents for protein site specific dye labeling.

Thompson DA, Evans EG, Kasza T, Millhauser GL, Dawson PE.

Biopolymers. 2014 May;102(3):273-9. doi: 10.1002/bip.22481.

7.

A new paradigm for enzymatic control of α-cleavage and β-cleavage of the prion protein.

McDonald AJ, Dibble JP, Evans EG, Millhauser GL.

J Biol Chem. 2014 Jan 10;289(2):803-13. doi: 10.1074/jbc.M113.502351. Epub 2013 Nov 18.

8.

Mechanistic study on the solution-phase n-doping of 1,3-dimethyl-2-aryl-2,3-dihydro-1H-benzoimidazole derivatives.

Naab BD, Guo S, Olthof S, Evans EG, Wei P, Millhauser GL, Kahn A, Barlow S, Marder SR, Bao Z.

J Am Chem Soc. 2013 Oct 9;135(40):15018-25. doi: 10.1021/ja403906d. Epub 2013 Sep 24.

9.

Zinc drives a tertiary fold in the prion protein with familial disease mutation sites at the interface.

Spevacek AR, Evans EG, Miller JL, Meyer HC, Pelton JG, Millhauser GL.

Structure. 2013 Feb 5;21(2):236-46. doi: 10.1016/j.str.2012.12.002. Epub 2013 Jan 3.

10.

Travel distance as factor in follow-up visit compliance in postlaparoscopic adjustable gastric banding population.

DeNino WF, Osler T, Evans EG, Forgione PM.

Surg Obes Relat Dis. 2010 Nov-Dec;6(6):597-600. doi: 10.1016/j.soard.2010.09.008. Epub 2010 Sep 17.

PMID:
21111380
11.

Histoplasmosis in Europe: report on an epidemiological survey from the European Confederation of Medical Mycology Working Group.

Ashbee HR, Evans EG, Viviani MA, Dupont B, Chryssanthou E, Surmont I, Tomsikova A, Vachkov P, Enero B, Zala J, Tintelnot K; ECMM Working Group on; Histoplasmosis.

Med Mycol. 2008 Feb;46(1):57-65.

PMID:
17885939
12.

Single strains of Trichophyton rubrum in cases of tinea pedis.

Rad MM, Jackson C, Barton RC, Evans EG.

J Med Microbiol. 2005 Aug;54(Pt 8):725-6.

PMID:
16014424
13.

Testing of antifungal combinations against yeasts and dermatophytes.

Harman S, Ashbee HR, Evans EG.

J Dermatolog Treat. 2004 Apr;15(2):104-7.

PMID:
15204161
14.

Restriction fragment length polymorphism analysis of ribosomal DNA intergenic regions is useful for differentiating strains of Trichophyton mentagrophytes.

Mochizuki T, Ishizaki H, Barton RC, Moore MK, Jackson CJ, Kelly SL, Evans EG.

J Clin Microbiol. 2003 Oct;41(10):4583-8.

15.

Drug synergies and the potential for combination therapy in onychomycosis.

Evans EG.

Br J Dermatol. 2003 Sep;149 Suppl 65:11-3. Review.

PMID:
14510970
16.

A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations.

Barrett JP, Vardulaki KA, Conlon C, Cooke J, Daza-Ramirez P, Evans EG, Hawkey PM, Herbrecht R, Marks DI, Moraleda JM, Park GR, Senn SJ, Viscoli C; Amphotericin B Systematic Review Study Group.

Clin Ther. 2003 May;25(5):1295-320. Review.

PMID:
12867214
17.

Prediction of outcome in the treatment of onychomycosis.

Sommer S, Sheehan-Dare RA, Goodfield MJ, Evans EG.

Clin Exp Dermatol. 2003 Jul;28(4):425-8.

PMID:
12823307
18.

Molecular strain typing of Trichophyton rubrum indicates multiple strain involvement in onychomycosis.

Yazdanparast A, Jackson CJ, Barton RC, Evans EG.

Br J Dermatol. 2003 Jan;148(1):51-4.

PMID:
12534594
19.

Prognostic factors of mycological cure following treatment of onychomycosis with oral antifungal agents.

Sigurgeirsson B, Paul C, Curran D, Evans EG.

Br J Dermatol. 2002 Dec;147(6):1241-3.

PMID:
12452877
20.

Skin colonization by Malassezia in neonates and infants.

Ashbee HR, Leck AK, Puntis JW, Parsons WJ, Evans EG.

Infect Control Hosp Epidemiol. 2002 Apr;23(4):212-6.

PMID:
12002236
21.

Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study.

Sigurgeirsson B, Olafsson JH, Steinsson JB, Paul C, Billstein S, Evans EG.

Arch Dermatol. 2002 Mar;138(3):353-7.

PMID:
11902986
22.

Immunology of diseases associated with Malassezia species.

Ashbee HR, Evans EG.

Clin Microbiol Rev. 2002 Jan;15(1):21-57. Review.

23.

The rationale for combination therapy.

Evans EG.

Br J Dermatol. 2001 Oct;145 Suppl 60:9-13. Review.

PMID:
11777263
24.

Post-traumatic fungal keratitis caused by Absidia corymbifera, with successful medical treatment.

Narain S, Mitra M, Barton RC, Evans EG, Hutchinson C.

Eye (Lond). 2001 Jun;15(Pt 3):352-3. No abstract available.

PMID:
11450745
25.

A two year global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion.

Liebowitz LD, Ashbee HR, Evans EG, Chong Y, Mallatova N, Zaidi M, Gibbs D; Global Antifungal Surveillance Group.

Diagn Microbiol Infect Dis. 2001 May-Jun;40(1-2):27-33.

PMID:
11448560
26.

An investigation into the pathogenesis of vulvo-vaginal candidosis.

El-Din SS, Reynolds MT, Ashbee HR, Barton RC, Evans EG.

Sex Transm Infect. 2001 Jun;77(3):179-83.

27.

Vaginal yeasts in the era of "over the counter" antifungals.

Walker PP, Reynolds MT, Ashbee HR, Brown C, Evans EG.

Sex Transm Infect. 2000 Dec;76(6):437-8.

28.

Training medical myocologists in developing countries.

Evans EG, Bulmer GS, Aly R, Coo-Barcelona L, Chakrabarti A, De Elias-Costa MR, Gugnani HC.

Med Mycol. 2000;38 Suppl 1:33-40.

PMID:
11204161
29.

Current and future approaches to antimycotic treatment in the era of resistant fungi and immunocompromised hosts.

Bastert J, Schaller M, Korting HC, Evans EG.

Int J Antimicrob Agents. 2001 Feb;17(2):81-91. Review.

PMID:
11165110
30.
31.

Trichophyton tonsurans tinea capitis and tinea corporis: treatment and follow-up of four affected family members.

Ravenscroft J, Goodfield MJ, Evans EG.

Pediatr Dermatol. 2000 Sep-Oct;17(5):407-9.

PMID:
11085674
32.

Non-tuberculous mycobacterial lung infection complicated by chronic necrotising pulmonary aspergillosis.

Hafeez I, Muers MF, Murphy SA, Evans EG, Barton RC, McWhinney P.

Thorax. 2000 Aug;55(8):717-9.

33.
34.

L.I.ON. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. Itraconazole in Onychomycosis.

Sigurgeirsson B, Billstein S, Rantanen T, Ruzicka T, di Fonzo E, Vermeer BJ, Goodfield MJ, Evans EG.

Br J Dermatol. 1999 Nov;141 Suppl 56:5-14.

PMID:
10730908
35.

Treatment of superficial white onychomycosis with topical terbinafine cream.

Goodfield MJ, Evans EG.

Br J Dermatol. 1999 Sep;141(3):604-5. No abstract available.

PMID:
10583101
36.

Microbiological and molecular diagnosis of deep localized cutaneous infection with Trichophyton mentagrophytes.

Sommer S, Barton RC, Wilkinson SM, Merchant WJ, Evans EG, Moore MK.

Br J Dermatol. 1999 Aug;141(2):323-5.

PMID:
10468809
37.

Invasive aspergillosis in two patients with Pearson syndrome.

Warris A, Verweij PE, Barton R, Crabbe DC, Evans EG, Meis JF.

Pediatr Infect Dis J. 1999 Aug;18(8):739-41. No abstract available.

PMID:
10462353
38.
40.

Analysis of peptidogalactomannans from the mycelial surface of Aspergillus fumigatus.

Haido RM, Silva MH, Ejzemberg R, Leitão EA, Hearn VM, Evans EG, Barreto Bergter E.

Med Mycol. 1998 Oct;36(5):313-21.

PMID:
10075501
41.
42.
43.

The ISHAM resolution 1997. International Society for Human and Animal Mycology.

Müller J, Evans EG.

Mycoses. 1998 Sep-Oct;41(7-8):263. No abstract available.

PMID:
9861828
44.

Detection of Aspergillus fumigatus PCR products by a microtitre plate based DNA hybridisation assay.

Fletcher HA, Barton RC, Verweij PE, Evans EG.

J Clin Pathol. 1998 Aug;51(8):617-20.

45.

Identification and purification of specific Penicillium marneffei antigens and their recognition by human immune sera.

Jeavons L, Hamilton AJ, Vanittanakom N, Ungpakorn R, Evans EG, Sirisanthana T, Hay RJ.

J Clin Microbiol. 1998 Apr;36(4):949-54.

46.

Causative pathogens in onychomycosis and the possibility of treatment resistance: a review.

Evans EG.

J Am Acad Dermatol. 1998 May;38(5 Pt 3):S32-36. Review.

PMID:
9594934
47.

Subungual dermatophytoma complicating dermatophyte onychomycosis.

Roberts DT, Evans EG.

Br J Dermatol. 1998 Jan;138(1):189-90. No abstract available.

PMID:
9536247
48.

Cryopreservation of Aspergillus fumigatus stock cultures with a commercial bead system.

Belkacemi L, Barton RC, Evans EG.

Mycoses. 1997 Sep;40(3-4):103-4.

PMID:
9375496
49.

Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. British Society for Medical Mycology.

Denning DW, Evans EG, Kibbler CC, Richardson MD, Roberts MM, Rogers TR, Warnock DW, Warren RE.

Eur J Clin Microbiol Infect Dis. 1997 Jun;16(6):424-36.

PMID:
9248745
50.

Tinea pedis: clinical experience and efficacy of short treatment.

Evans EG.

Dermatology. 1997;194 Suppl 1:3-6. Review.

PMID:
9154392

Supplemental Content

Loading ...
Support Center